Study on the Effects of a Sleep Aid on Beta-Amyloid and Tau Protein Levels
A study led by neurologist Brendan Lucey found that the sleep medication suvorexant can reduce levels of beta-amyloid and tau protein in healthy middle-aged adults. This discovery could have implications for dementia prevention, as abnormal buildup of these proteins is associated with Alzheimer's disease. The two-day experiment involved 38 participants who stayed in a sleep clinic.
Participants, aged 45 to 65, received varying doses of suvorexant or a placebo. Fluid samples were collected every two hours, allowing researchers to observe a modest decrease in beta-amyloid and tau protein levels. At the standard therapeutic dose, beta-amyloid concentration dropped by 10–20% compared to the placebo, while a higher dose temporarily reduced levels of modified tau protein.
Outlook and Risks of Using Sleep Medications
It is worth noting that sleep disturbances are often an early sign of Alzheimer's disease. The amyloid hypothesis of the disease's origin is being questioned, and the potential use of sleep aids for dementia prevention requires further investigation. Study leader Brendan Lucey stated that
“interpreting these data as a call for regular medication use is premature.”
Additionally, long-term use of sleep medications carries risks, such as dependency and reduced deep sleep phases. These findings are considered preliminary, and further studies are needed to confirm the potential of sleep aids in preventing dementia in older adults.
Brendan Lucey's research highlights the importance of studying the impact of sleep on the development of neurodegenerative diseases. While the results are promising, they require further investigation to determine the safety and effectiveness of using sleep medications for dementia prevention. Given the potential risks associated with long-term use of such drugs, it is crucial to approach their use cautiously and consider individual patient needs.